Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.

Video: Tengion Neo-Urinary Conduit™

Watch as the neo-urinary conduit development process is described for use in patients with bladder cancer.

* IE users only: You may be redirected to upgrade
security components and install an Active X control.

The video you are linking to depicts experimental technology invented by, and procedures performed at, Children's Hospital Boston. This technology serves as the foundation for Tengion's lead product candidate, the Neo-Bladder Augment, which is currently in Phase 2 clinical trials. Tengion's Neo-Bladder Augment is investigational and has not been approved by the FDA for commercial sale. Additionally, the Neo-Bladder Augment may not be appropriate for all patients and medical results depicted in this video may not be experienced by others using this technology.

Tengion Provides Business Update and Reports First Quarter 2012 Financial Results May 7, 2012

Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2012 Financial Results on May 7, 2012 April 30, 2012

Tengion Announces IND Filing for Neo-Kidney Augment Expected During First Half of 2013 April 17, 2012

Tengion Announces Listing Transfer from NASDAQ Global Market® to NASDAQ Capital Market® April 3, 2012

Tengion Reports Fourth Quarter and Full Year 2011 Financial Results March 26, 2012

Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.

All News »